Reactions 1680, p333 - 2 Dec 2017 DRESS syndrome: case report A 51-year-old man developed DRESS syndrome during treatment with vemurafenib [route and dosage not stated]. The man with lentigo maligna melanoma of the ear was referred for lung, brain, liver and subcutaneous metastases at the age of 46 years. Five years later, he was initiated on vemurafenib treatment due to the progression of lung metastases. After 21 days of vemurafenib initiation, he presented with maculopapular exanthema and facial oedema. His laboratory tests showed eosinophilia with liver cytolysis and renal insufficiency. Consequently, he was diagnosed with DRESS syndrome, with a REGISCAR score of 6. As he was only receiving treatment with vemurafenib; his DRESS syndrome was considered to be caused by vemurafenib. As a result, the man’s vemurafenib was discontinued. He was initiated on corrective treatment with topical corticosteroids and prednisone. Within two weeks of vemurafenib discontinuation and start of corticosteroids, his laboratory tests and clinical condition improved. He was then started on nivolumab, followed by ipilimumab for the treatment of metastatic lentigo maligna melanoma. However, due to the progression of liver and a new bone metastasis, dabrafenib was started. He achieved partial remission during treatment with dabrafenib, without any recurrence of DRESS syndrome. Author comment: "We report the case of a patient with metastatic malignant melanoma in whom DRESS developed likely from vemurafenib." Pinard C, et al. Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib. JAAD Case Reports 3: 532-533, No. 6, Nov 2017. Available from: URL: http:// doi.org/10.1016/j.jdcr.2017.06.027 - France 803285387 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud